1 Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): cases in the U.S. https://www.cdc.gov/coronavirus/ 2019-ncov/cases-updates/cases-in-us.html (accessed April 28, 2020).
2 New York State Department of Health. COVID-19 tracker. https://covid19tracker.health.ny.gov/views/NYS-COVID19-Tracker/ NYSDOHCOVID-19Tracker-Map?%3Aembed=yes&%3Atoolbar=no &%3Atabs=n (accessed April 28, 2020).
3 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; published online Feb 24. DOI:10.1001/jama.2020.2648. [OpenAIRE]
4 Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708-20.
5 Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA 2020; published online March 13. DOI:10.1001/jama.2020.4031. [OpenAIRE]
6 Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study. Lancet Respir Med 2020; published online Feb 24. https://dx.doi.org/10.1016/ S2213-2600(20)30079-5.
7 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-62.
8 Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020; published online April 6. DOI:10.1001/jama.2020.5394.
9 Arentz M, Yim E, Klaf L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 2020; published online March 19. DOI:10.1001/jama.2020.4326.
10 Bhatraju PK, Ghassemieh BJ, Nichols M, et al. COVID-19 in critically ill patients in the Seattle region-case series. N Engl J Med 2020; published online March 30. DOI:10.1056/ NEJMoa2004500.
11 WHO. R&D Blueprint: COVID-19 therapeutic trial synopsis. Feb 18, 2020. https://www.who.int/blueprint/priority-diseases/keyaction/COVID-19_Treatment_Trial_Design_Master_Protocol_ synopsis_Final_18022020.pdf (accessed April 11, 2020).
12 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033-34.
13 Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; published online May 4. DOI:10.1007/s00134-020-06062-x.
14 Kelly CA, Upex A, Bateman DN. Comparison of consciousness level assessment in the poisoned patient using the alert/verbal/painful/ unresponsive scale and the Glasgow Coma Scale. Ann Emerg Med 2004; 44: 108-13. [OpenAIRE]
15 CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 343-46.